UPSIDE Foods
Founded Year
2015Stage
Series C | AliveTotal Raised
$610.85MValuation
$0000Last Raised
$400M | 4 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-89 points in the past 30 days
About UPSIDE Foods
UPSIDE Foods specializes in the production of cultivated meat, which is grown directly from animal cells. The company focuses on providing an alternative to traditional meat production. It was founded in 2015 and is based in Berkeley, California.
Loading...
ESPs containing UPSIDE Foods
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The cultured meat market, also known as clean meat or cultivated meat, refers to companies that provide a more sustainable source of meat by culturing animal cells. Companies in this market focus on various types of meat, including chicken, pork, fish, and beef. While some of these companies are developing consumer brands, others are focused on building out white-label solutions for manufacturers.…
UPSIDE Foods named as Highflier among 15 other companies, including JUST Egg, Meatable, and Aleph Farms.
Loading...
Expert Collections containing UPSIDE Foods
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
UPSIDE Foods is included in 6 Expert Collections, including Agriculture Technology (Agtech).
Agriculture Technology (Agtech)
2,364 items
Companies in the agtech space, such as equipment manufacturers, surveying drones, geospatial intelligence firms, and farm management platforms
Unicorns- Billion Dollar Startups
1,309 items
Food & Beverage
2,802 items
Startups in the food & beverage space, including alternative proteins, vertically-farmed produce, functional beverages and more.
Alternative Proteins
408 items
This Collection includes B2B and B2C companies developing alternatives to animal-derived proteins, including plant-based meat, dairy alternatives, lab-grown or cultured meat, and fermented proteins.
Game Changers 2018
70 items
Wellness Tech
1,370 items
We define wellness tech as companies developing technology to help consumers improve their physical, mental, and social well-being. Companies in this collection play across a wide range of categories, including food and beverage, fitness, personal care, and corporate wellness.
UPSIDE Foods Patents
UPSIDE Foods has filed 62 patents.
The 3 most popular patent topics include:
- biotechnology
- meat industry
- cell biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/12/2024 | 3/25/2025 | Fluid dynamics, Aerodynamics, Smoked meat, Dried meat, Meat industry | Grant |
Application Date | 2/12/2024 |
|---|---|
Grant Date | 3/25/2025 |
Title | |
Related Topics | Fluid dynamics, Aerodynamics, Smoked meat, Dried meat, Meat industry |
Status | Grant |
Latest UPSIDE Foods News
Oct 9, 2025
MSCs are multipotent cells that have been referred to as mesenchymal stem cells, medicinal signaling cells, and mesenchymal stromal cells, reflecting their versatility and diverse applications. MSCs can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes. Their unique ability to secrete factors that promote tissue repair and modulate their microenvironment with anti-inflammatory and anti-fibrotic effects makes them essential in regenerative medicine. Furthermore, their immuno-evasive properties make MSCs particularly suitable for allogenic transplantation. MSCs serve as vital raw materials across numerous industries, including regenerative medicine, cosmeceuticals, and cultured meat production. Key applications include: Specifically, the Republic of Korea has approved five products: Queencell from Anterogen, Cellgram AMI from Pharmicell, Cupistem from Anterogen, Cartistem from Medipost, and NeuroNataR from Corestem. Japan has approved two products: Temcell HS from JCR Pharmaceuticals and Stemirac from Nipro Corporation. The EMA in Europe has approved two products: Holoclar from Chiesi Farmaceutici and Alofisel from TiGenix/Takeda. India has approved one product: Stempeucel from Stempeutics. Iran has approved one product: MesestroCell developed by Cell Tech Pharmed. Finally, Australia has approved one product: Remestemcel-L from Mesoblast. Despite this progress, no MSC-based therapeutic have yet received U.S. FDA approval, although the FDA is actively reviewing Mesoblast's Remestemcel-L. The cosmeceutical market is also rapidly adopting MSC-derived products, particularly exosomes, to leverage their anti-aging and regenerative properties, with companies like L'Oreal and Johnson & Johnson investing heavily in this space. Similarly, cultured meat companies are utilizing MSCs for producing muscle and fat cells, enhancing taste and texture. Groundbreaking approvals, such as lab-grown chicken by Upside Foods and Good Meat, have paved the way for further growth in this industry. MSC-based gene editing is expanding, enabling the overexpression of antitumor genes and therapeutic factors. Researchers are also exploring the use of MSCs in 3D printing and engineered organ production, with breakthroughs anticipated in the next decade. Importantly, companies like Cynata Therapeutics are pioneering iPSC-derived MSC production technologies, enabling large-scale therapeutic development. Today there are at least eight companies who are involved with the development of iPSC-derived MSCs therapeutics (iMSCs), including Cynata Therapeutics, Eterna Therapeutics, Implant Therapeutics, Bone Therapeutics, Brooklyn ImmunoTherapeutics, Fujifilm CDI, Citius Pharmaceuticals, and Kiji Therapeutics. There are also over 1,670 clinical trials involving MSCs are registered on ClinicalTrials.gov. Nearly 75% (three-quarters) of these clinical studies are using MSCs for the development of regenerative medicine (RM) products. Approximately 14% of the studies are using MSCs for disease modeling. The remaining 11% of the studies are using MSCs for drug discovery and cytotoxicity testing applications. Challenges in these trials include maintaining MSC phenotype and functionality during expansion. However, ongoing advancements suggest a promising future, with projections for at least 50 globally approved MSC-based products by 2040, averaging 3-4 new approvals annually. Key Players in MSC Research Products The demand for MSC-based research products has surged in recent years, with major suppliers expanding their portfolios. Companies like RoosterBio have increased the access to quality MSCs through supply chain industrialization, standardized cell bank product forms, and fit-for-purpose cGMP-compatible cells and media systems. Other leading MSC research product suppliers include PromoCell, Lonza, Thermo Fisher Scientific, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne (R&D Systems), ScienCell Research Laboratories, and the ATCC. Challenges and Opportunities While MSC commercialization faces hurdles-such as scalability and regulatory approval-opportunities abound. The market for MSC-based products is poised for notable growth across the research, therapeutic, cosmetic, and food industries. Within this rapidly changing landscape, having a thorough understanding of the competition is essential. This global strategic report presents rates of MSC clinical trials, scientific publications, patents, funding events, and collaborations. It presents the pipeline for MSC-based therapeutics, identifies market opportunities and threats, and explores future directions and emerging applications. It reveals innovative MSC products, services, and technologies offered by 125 leading competitors. Finally, it presents detailed market size figures for the global MSC market, segmented by geography and business segment with future forecasts through 2031. Key Topics Covered: 1. REPORT OVERVIEW 2. MESENCHYMAL STEM CELLS (MSCs): AN OVERVIEW 2.1 Stabilization of Human MSCs (hMSCs) as a Technology 2.2 The Impact of MSCs on Regenerative Medicine 2.3 Timeline of MSC Nomenclature 2.4 Sources of MSCs 2.5 Cell Surface Markers in MSCs 2.6 In vitro Differentiation Potentials of MSCs 2.7 Soluble Factors Secreted by MSCs 2.8 Stemness Genes Present in MSCs 2.9 Types of MSCs and their Biomedical Applications 2.10 Genes that are Pivotal for MSCs' Properties 3. MSC-BASED CLINICAL TRIAL LANDSCAPE 3.1 MSC-Based Clinical Studies by Geography 3.2 Sources of MSCs used in Current Clinical Trials 3.3 Share of Autologous & Allogeneic MSCs Clinical Trials 3.4 MSC-Based Clinical Trials by Disease Indication 3.5 MSC-Based Clinical Trials by Phase of Study 3.6 Select MSC-Based Clinical Trials 4. MESENCHYMAL STEM CELLS (MSCS): PATENT LANDSCAPE 4.1 MSC Patent Publications by Jurisdiction 4.2 MSC Patent Applicants 4.3 MSC Patent Inventors 4.4 MSC Patent Owners 4.5 Legal Status of MSC Patent Applications 4.6 MSC-Derived Exosome Patents 4.7 Patents for iPSC-Derived MSCs (iMSCs) 4.8 MSC Patents by Therapy Type 5. PUBLISHED SCIENTIFIC PAPERS ON MSCS 5.1 PubMed.gov Published Papers on MSCs in Cell Therapy 5.2 PubMed.gov Published Papers on MSC-Based Immunotherapies 5.3 PubMed.gov Published Papers on MSCs in Gene Therapy 5.4 PubMed.gov Published Papers on MSCs in Tissue Engineering 5.5 PubMed.gov Published Papers on MSCs in Aesthetics 5.6 Number of Published Papers on the Applications of MSCs in Major Diseases 5.7 Published Papers on Modified MSCs 5.8 Published Papers on MSC-Derived Exosomes 6. MSC MANUFACTURING PLATFORMS: AN OVERVIEW 6.1 Methods of Isolations of MSCs 6.2 Cell Expansion: Conventional Cultures to Bioreactors 6.3 Downstream Processing of MSCs 6.4 Autologous & Allogeneic MSC Manufacturing: A Comparison 6.5 Large Scale Manufacturing of MSCs 7. CELL & GENE THERAPY CONTRACT MANUFACTURING 7.1 Staff Shortage 7.2 Need for Automation 7.3 Capacity Constraints 7.4 CDMO Platforms with Greater Potentials 7.5 CMOs/CDMOs 7.6 Geographic Distribution of Manufacturing Facilities 7.7 Continued Rise of Outsourcing 7.8 Major CDMOs in the U.S 7.9 Major Cell & Gene Therapy CDMOs in Europe 7.10 UK's Dominance in European Contract Manufacturing 8. BIOENGINEERING SOLUTIONS TO BOOST MSC FUNCTIONALITY 8.1 Small Molecule Priming of MSCs 8.2 Particle Engineering of MSCs 8.2.1 Materials used in Microparticles (MPs) Fabrication 8.3 Genetic Engineering of MSCs 8.4 Examples of Bioengineered MSCs to Produce Anticancer Therapeutics 8.5 Engineered MSCs for Neurological Conditions 8.6 Engineered MSCs for Cardiovascular Diseases 8.6 Engineered MSCs for Lung Injury 8.7 Engineered MSCs for Diabetes 8.8 Bioengineering Approaches to Improve MSC Administration 9. MAJOR DISEASES ADDRESSED BY MSCS 9.1 Studies Using MSCs for Autoimmune Diseases 9.2 Studies using MSCs for Cardiovascular Diseases 9.3 Studies using MSCs for Neurodegenerative Diseases 9.4 Studies using MSCs for Bone & Cartilage Diseases 9.5 Studies using MSCs in GvHD 9.6 Studies using MSCs in Crohn's Disease 9.7 Studies using MSCs in Type 1 Diabetes 9.8 Studies using MSCs in Systemic Lupus Erythematosus (SLE) 9.9 Studies using MSCs in Parkinson's Disease 9.10 Studies using MSCs in Alzheimer's Disease 9.11 Studies using MSCs in Kidney Failure 9.12 Studies using MSCs in Spinal Cord Injury 9.13 Studies using MSCs for Wound Healing 10. RECENT COLLABORATIONS WITHIN THE MSC SECTOR, 2020-2024 11. MSC-BASED PRODUCTS IN THE GLOBAL MARKET Approved MSC Therapies Marketed Biomaterial Carrier-Based MSCs & MSC Progenitors Topical Cosmetic Products Containing MSCs/MSC-Derived Exosomes 12. MARKET ANALYSIS 12.1 Market Size for MSC Therapies 12.2 Global Demand for Mesenchymal Stem Cells (MSCs) 13. COMPANY PROFILES For more information about this report visit https://www.researchandmarkets.com/r/42314k About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
UPSIDE Foods Frequently Asked Questions (FAQ)
When was UPSIDE Foods founded?
UPSIDE Foods was founded in 2015.
Where is UPSIDE Foods's headquarters?
UPSIDE Foods's headquarters is located at 804 Heinz Avenue, Berkeley.
What is UPSIDE Foods's latest funding round?
UPSIDE Foods's latest funding round is Series C.
How much did UPSIDE Foods raise?
UPSIDE Foods raised a total of $610.85M.
Who are the investors of UPSIDE Foods?
Investors of UPSIDE Foods include SOSV, IndieBio, SoftBank, Bill Gates, Kimbal Musk and 41 more.
Who are UPSIDE Foods's competitors?
Competitors of UPSIDE Foods include Aleph Farms, The Abbot's Butcher, SeaWith, Planted, Uncommon and 7 more.
Loading...
Compare UPSIDE Foods to Competitors
SuperMeat is a food tech company focused on the production of cultivated meat, particularly chicken, using a process that claims to be sustainable and animal-friendly. The company offers cultivated meat products that provide nutritional security for carbon emissions, and food safety. It was founded in 2015 and is based in Tel Aviv, Israel.
Aleph Farms is a food technology company that specializes in cell-grown meat. It grows beef steaks from non-genetically engineered and non-immortalized cells isolated from a living cow without slaughtering the animals. The company was founded in 2017 and is based in Rehovot, Israel.
Believer Meats focuses on the production of cultivated meat within the food technology sector. It offers real, non-GMO meat grown from animal cells, providing a cruelty-free, antibiotic-free, and environmentally friendly alternative to conventionally farmed meat. The company primarily serves consumers looking for healthier and sustainable meat options. Believer Meats was formerly known as Future Meat Technologies. It was founded in 2018 and is based in Rehovot, Israel.
Mosa Meat focuses on beef alternatives within the food industry. The company specializes in producing cultured beef burgers, utilizing cell-based meat technology to create real beef without the need to raise and slaughter animals. It primarily serves the food industry. The company was founded in 2013 and is based in Maastricht, Netherlands.
Prime Roots is a company that creates plant-based protein products in the deli meat alternative sector. Their offerings include a variety of deli meats and bacon substitutes that aim to replicate traditional meats, using ingredients without preservatives. The company serves the foodservice industry and consumers looking for plant-based alternatives to deli meats. Prime Roots was formerly known as Terramino Foods. It was founded in 2017 and is based in Berkeley, California.
Rebellyous Foods specializes in the production of plant-based chicken alternatives within the food industry. Its main offerings include a variety of nuggets, patties, and tenders designed to replicate the taste and texture of traditional chicken products. The company primarily serves the retail, food service, and educational sectors of food options. It was formerly known as Seattle Food Tech. It was founded in 2017 and is based in Seattle, Washington.
Loading...